Junsaku Kitagawa

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima et al. · Neuro-Oncology · 2020 · 170 citations · Full text

Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting

Susumu Nakade, Tomoya Ohno, Junsaku Kitagawa et al. · Cancer Chemotherapy and Pharmacology · 2008 · 54 citations

Drug Safety, Chemotherapy-induced Nausea, Pharmacology +6

Absolute bioavailability of imidafenacin after oral administration to healthy subjects

Tomoya Ohno, Susumu Nakade, Kazuki Nakayama et al. · British Journal of Clinical Pharmacology · 2007 · 31 citations · Full text

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19

Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida et al. · Clinical and Translational Science · 2021 · 28 citations · Full text

The prediction of human response to ONO‐4641, a sphingosine 1‐phosphate receptor modulator, from preclinical data based on pharmacokinetic–pharmacodynamic modeling

Tomoya Ohno, Chihiro Hasegawa, Susumu Nakade et al. · Biopharmaceutics & Drug Disposition · 2010 · 21 citations